E.R. Squibb & Sons, L.L.C.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$150Mgeneral payments (2019-2025)
$23Mresearch payments (2019-2025)
166,484clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Sotyktu $14M associated (2023-2025)
- Cobenfy $14M associated (2023-2025)
- Opdivo $8.3M associated (2023-2025)
- Camzyos $8.2M associated (2023-2025)
- Zeposia $6.1M associated (2023-2025)
- Reblozyl $3.2M associated (2023-2025)
- Eliquis $2.4M associated (2023-2025)
- Pomalyst $873K associated (2023-2025)
- Breyanzi $872K associated (2023-2025)
- Orencia $439K associated (2023-2025)
- Onureg $346K associated (2023-2025)
- Abecma $280K associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Laurie Glimcher | New York, NY | Rheumatology | $790,531.51 |
| Martin Dietrich | Rockledge, FL | Hematology & Oncology | $751,659.56 |
| Steven Baranowitz | Brooklyn, NY | Dermatology | $625,250.00 |
| Joan Ryan | Lake Bluff, IL | $602,985.80 | |
| Devesh Pandya | Houston, TX | Hematology & Oncology | $519,588.18 |
| Thomas Leblanc | Durham, NC | Medical Oncology | $498,574.27 |
| Eric Whitman | Morristown, NJ | Surgery | $492,328.45 |
| Ronan Kelly | Dallas, TX | Medical Oncology | $480,320.30 |
| Kent Shih | Nashville, TN | Hematology & Oncology | $473,055.66 |
| Tarek Mekhail | Orlando, FL | Hematology & Oncology | $457,535.90 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.